| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 08/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/24/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/02/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ... |
| 05/25/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/16/2023 |
8-K
| Investor presentation |
| 04/19/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 7.5% stake in Aravive, Inc. |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| HOWARD RUDY (CFO) has filed a Form 4 on Aravive, Inc.|
Txns:
| Granted 400,000 options to buy
@ $1.67, valued at
$668k
|
|
| 02/02/2023 |
4
| Dove Leonard Scott (COO) has filed a Form 4 on Aravive, Inc.|
Txns:
| Granted 400,000 options to buy
@ $1.67, valued at
$668k
|
|
| 01/18/2023 |
8-K
| Quarterly results |
| 01/04/2023 |
8-K
| Quarterly results |
| 01/03/2023 |
8-K
| Quarterly results |
| 01/03/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 12/28/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/27/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/30/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/29/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/29/2022 |
8-K
| Quarterly results |
| 11/29/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/18/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 11/17/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 11/16/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/07/2022 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Aravive, Inc. |
| 11/03/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
|